Completed PHASE2 INTERVENTIONAL 2-arm NCT00125502

Recombinant CMV gB Vaccine in Postpartum Women

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Recombinant CMV gB Vaccine in Postpartum Women

Sponsor: MCM Vaccines B.V.

Conditions Cytomegalovirus Infections

Interventions CMV gB vaccine MF59 adjuvant Placebo

Updated 6 times since 2017 Last updated: Sep 16, 2011 Started: Aug 31, 1999 Primary completion: Jun 30, 2007 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cytomegalovirus Infections and is currently completed. MCM Vaccines B.V. leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MCM Vaccines B.V.
National Institute of Allergy and Infectious Diseases (NIAID)
Robert Pass, MD

Data source: University of Alabama at Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United States
• Tuscaloosa, United States